Educational Activities Archives

Stimulant use, including cocaine, methamphetamine and prescription stimulants, continues to be a growing and urgent public health concern. According to the 2024 National Survey on Drug Use and Health, 9 million people in the U.S. had used stimulants not as prescribed in the past year. Though opioids are often the focus of overdose conversations, stimulant-related overdose deaths reached an estimated 51,630 in 2024, while 59% of all overdoses from January 2021 through June 2024 involved a stimulant (Centers for Disease Control and Prevention, 2025). These trends underscore the critical need for effective treatment and engagement strategies. Several evidence-based behavioral therapies exist to help providers treat stimulant use disorder. This webinar will outline the clinical and administrative approaches to assess, treat and support people experiencing stimulant use disorder.

Mutual-help organizations (MHOs) such as Alcoholic Anonymous, SMART Recovery, LifeRing and many others, are ubiquitous across the United States and are found in small, medium, and large cities. They can be a valuable addition to treatment plans and extend the reach of the clinician by providing their patients with ongoing paths to recovery via crucial sober social support that has been found to confer valuable relapse prevention skills. This presentation provides education about the origin, types, scope, and theoretical orientation of a variety of MHOs, including new evidence for their clinical and public health utility, as well as evidence on why they are so helpful. Examples of proven clinical strategies to enhance involvement with MHOs during and following treatment will be provided including for those patients taking medications.

Over 2.5 million adults in the U.S. are diagnosed with OUD. In 2022, 12.7% of ED visits involved opioids. Yet only 25% of those who need treatment receive recommended MOUD. MOUDs are highly effective treatments that have been shown to decrease opioid use, cravings and transmission of infectious disease, and to increase retention in treatment. As the opioid epidemic continues to impact people across the U.S., the ED represents a critical access point to the health care system, supporting people with OUD by initiating MOUD, such as buprenorphine, and connecting them to low-threshold, easy-to-access care for continued treatment.

Provides a basic introduction of the concepts of the disease of addiction and the role of the reward system. Using neuroscience concepts as a foundation, clinical manifestations of the disease of addiction are then discussed in the form of case-based presentations. 

Outlines the basic concepts of alcohol and drug use disorders. Standard drink sizes, screening for alcohol use disorders and an introduction to alcohol withdrawal management are discussed. A basic overview of the major drug use disorders are then discussed in a clinically-relevant manner. 

Provides an overview of the history of opioid use with an overview of contributing factors to the current epidemic. Using clinical cases, opioid use disorder is then discussed in detail. Finally, there is a discussion of treatment options.